PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia

Cellular and Molecular Biology

Volumn 62, Issue 8, 2016, Pages 52-55

  Yousefi, B ^a,b,c   Shafiei Irannejad, V ^a,b,d   Azimi, A ^c   Samadi, Nasser ^a   Zarghami, Nosratollah ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MARAGHEH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; CML; Drug resistance; Imatinib; PPAR

Indexed keywords

ANTHRACYCLINE; BALAGLITAZONE; BCR ABL PROTEIN; CHLORMETHINE; CIGLITAZONE; DASATINIB; IMATINIB; NILOTINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REGLITAZAR; ROSIGLITAZONE; TROGLITAZONE; VINCA ALKALOID; PROTEIN KINASE INHIBITOR;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; HUMAN; SHORT SURVEY; BIOLOGICAL MODEL; DRUG RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PPAR GAMMA; PROTEIN KINASE INHIBITORS;

EID: 84994896459     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2016.62.8.9     Document Type: Short Survey

References (41)

1. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-40.
2. YousefiB, Samadi N, Baradaran B, Shafiei-Irannejad V, Zarghami N. Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: Therapeutic strategies. Chem Biol Drug Des. in press, accepted: Feberary 3, 2016.
3. Curi A, Beauchamp M, Platanias C. Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia. Leuk Lymphoma 2015; 56:1581-2.
4. Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31:1397-407.
5. Holohan C, Van Schaeybroeck S, Longley D, Johnston P. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26.
6. Lamontanara A, Gencer E, Kuzyk O, Hantschel O. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta (BBA)-Proteins and Proteomics 2013; 1834:1449-59.
7. Yeung D, Hughes T. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit Rev Oncog 2012; 17:17-30.
8. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013; 4:103-117.
9. Hochhaus A, Saglio G, Larson R A, Kim DW, Etienne G, Rosti G, et al. Nilotinib is associated with a reduced incidence of BCRABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121:3703-08.
10. Lin YL, Meng Y, Jiang W, Roux B. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc Natl Acad Sci U S A 2013; 110:1664-69.
11. Khoury H J, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119:3403-12.
12. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 2012; 109:1643-48.
13. Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol 2014; 34:1722-32.
14. Hoekstra D, Carlson L, Lee K. Rewiring of the Bcr/Abl and PKC β II signal transduction pathways (P4322). J Immunol 2013, 190:45-9.
15. Zhang W, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27:3642-49.
16. YousefiB, Zarghami N, Samadi N, Majidinia M. Peroxisome Proliferator-activated Receptors and their ligands in cancer drug resistance: opportunity or challenge. Anticancer Agents Med Chem. in press, accepted: Feberary 3, 2016.
17. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARa. Nature 2002; 415:813-17.
18. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007; 1771:915-25.
19. Saliani N, Darabi M, YousefiB, Baradaran B, Khaniani MS, Darabi M, et al. PPARγ agonist-induced alterations in δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway World J Hepatol 2013; 5:220-25.
20. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8:532-51.
21. Nabholtz JM. Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001; 3:1-12.
22. Xue X, Liang XJ. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J cancer 2012; 31:100-109.
23. Liu Y, Han T, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001; 15:719-30.
24. Kast C. Gros P. Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J Biol Chem 1997; 272:26479-87.
25. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007-17.
26. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001; 33:453-58.
27. YousefiB, Rahmati M, Ahmadi Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life sciences 2014; 99:14-17.
28. Gora J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem 2008; 15:3036-51.
29. Konopleva M, AndreeffM. Role of peroxisome proliferator-activated receptor-γ in hematologic malignancies. Curr Opin Hematol 2002; 9:294-302.
30. Greene M, Pitts J, McCarville M, Wang X, Newport J, Edelstein C, Lee F, et al. PPARγ: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat 2000; 62:45-73.
31. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95:3214-18.
32. Davies GF, Roesler WJ, Juurlink BH, Harkness TA. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 2005; 46:1199-206.
33. Davies G F, Juurlink BH, Harkness TA. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther 2009; 3:79-8.
34. Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang Y, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone-induced apoptosis in leukemia k562 cells and its mechanisms of action. Int J Toxicol 2009; 28:123-31.
35. Zhao H, Gu H, Zhang H, Li JH, Zhao WE. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone. Biochim Biophys Acta 2014; 1840:545-55.
36. Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K, et al. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 2006; 5:2237-43.
37. Bertz J, Zang C, Liu H, Wachter M, Possinger K, Koeffler HP, et al. Compound 48, a novel dual PPAR α/γ ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. Leuk Res 2009; 33:686-92.
38. B Yousefi, N Samadi, Y Ahmadi. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA repair 2014; 22: 24-29.
39. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104:3739-45.
40. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112:3348-33.
41. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 2015; 525:380-3.